208 related articles for article (PubMed ID: 12035132)
1. Mechanisms of action and potential therapeutic uses of thalidomide.
Mujagić H; Chabner BA; Mujagić Z
Croat Med J; 2002 Jun; 43(3):274-85. PubMed ID: 12035132
[TBL] [Abstract][Full Text] [Related]
2. [Novel potential uses of thalidomide in the management of pain? A review of the literature].
Peuckmann V; Strumpf M; Zenz M; Bruera E
Schmerz; 2003 Jun; 17(3):204-10. PubMed ID: 12789488
[TBL] [Abstract][Full Text] [Related]
3. Potential novel uses of thalidomide: focus on palliative care.
Peuckmann V; Fisch M; Bruera E
Drugs; 2000 Aug; 60(2):273-92. PubMed ID: 10983733
[TBL] [Abstract][Full Text] [Related]
4. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Maier SK; Hammond JM
Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
[TBL] [Abstract][Full Text] [Related]
5. [Thalidomide--new prospective therapy in oncology].
Pałgan K; Pałgan I
Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
[TBL] [Abstract][Full Text] [Related]
6. Thalidomid: current role in the treatment of non-plasma cell malignancies.
Kumar S; Witzig TE; Rajkumar SV
J Clin Oncol; 2004 Jun; 22(12):2477-88. PubMed ID: 15197211
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide: present and future in multiple myeloma.
Hussein MA
Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
[TBL] [Abstract][Full Text] [Related]
8. Dermatologic therapeutics: thalidomide. A practical guide.
Rosenbach M; Werth VP
Dermatol Ther; 2007; 20(4):175-86. PubMed ID: 17970884
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide in the treatment of multiple myeloma.
Rajkumar SV
Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide: the tragedy of birth defects and the effective treatment of disease.
Kim JH; Scialli AR
Toxicol Sci; 2011 Jul; 122(1):1-6. PubMed ID: 21507989
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide: an old sedative-hypnotic with anticancer activity?
Gasparini G; Morabito A; Magnani E; Gattuso D; Capaccetti B; Alberti AM
Curr Opin Investig Drugs; 2001 Sep; 2(9):1302-8. PubMed ID: 11717819
[TBL] [Abstract][Full Text] [Related]
12. [Should thalidomide be rehabilitated?].
Belaube P; Garcin G; Marchand JP; Privat Y
Sem Hop; 1983 Dec; 59(45):3101-4. PubMed ID: 6320398
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide as a novel therapeutic agent: new uses for an old product.
Teo SK; Stirling DI; Zeldis JB
Drug Discov Today; 2005 Jan; 10(2):107-14. PubMed ID: 15718159
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
15. [Thalidomide: new uses for an old drug].
Wu KL; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1438-41. PubMed ID: 12190008
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Ortega J; List A
Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide: from teratogen to anti-angiogenic.
Grover JK; Vats K
Indian J Cancer; 2001 Mar; 38(1):22-32. PubMed ID: 14758882
[TBL] [Abstract][Full Text] [Related]
18. Adverse effects of thalidomide administration in patients with neoplastic diseases.
Dimopoulos MA; Eleutherakis-Papaiakovou V
Am J Med; 2004 Oct; 117(7):508-15. PubMed ID: 15464708
[TBL] [Abstract][Full Text] [Related]
19. The role of thalidomide in the management of erythema nodosum leprosum.
Walker SL; Waters MF; Lockwood DN
Lepr Rev; 2007 Sep; 78(3):197-215. PubMed ID: 18035771
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?
Sekeres MA; List A
Curr Hematol Rep; 2005 May; 4(3):182-5. PubMed ID: 15865869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
